Ultraschall Med 2022; 43(01): 82-89
DOI: 10.1055/a-1149-9092
Original Article

Gastrointestinal Ultrasound Can Predict Endoscopic Activity in Crohn’s Disease

Gastrointestinaler Ultraschall zur Prädiktion der endoskopischen Krankheitsaktivität bei Morbus Crohn
Fredrik Sævik
1   National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway
2   Department of Clinical Medicine, University of Bergen, Norway
Odd Helge Gilja
1   National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway
2   Department of Clinical Medicine, University of Bergen, Norway
Kim Nylund
1   National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway
2   Department of Clinical Medicine, University of Bergen, Norway
› Author Affiliations


Purpose To explore the ability of gastrointestinal ultrasound (GIUS) to separate patients in endoscopic remission from patients with active disease in a heterogeneous hospital cohort with Crohn’s disease (CD).

Materials and Methods 145 CD patients scheduled for ileocolonoscopy were prospectively included. The endoscopic disease activity was quantified using the Simple Endoscopic Score for Crohn’s disease (SES-CD), and mucosal healing was strictly defined as SES-CD = 0. Ultrasound remission was defined as wall thickness < 3 mm (< 4 mm in the rectum). Additionally, SES-CD was compared to color Doppler, Harvey Bradshaw’s index (HBI), C-reactive protein (CRP) and calprotectin. 23 patients were examined by two investigators for interobserver assessment.

Results 102 had active disease and 43 patients were in remission. GIUS yielded a sensitivity of 92.2 % and a specificity of 86 % for wall thickness and a sensitivity of 66.7 % and a specificity of 97.7 % for color Doppler. The sensitivity and specificity were 34.3 % and 88.4 %, respectively, for HBI, 35.7 % and 82.9 %, respectively, for CRP and 55.9 % and 82.1 %, respectively, for calprotectin. The interobserver analysis revealed excellent agreement for wall thickness (k = 0.90) and color Doppler (k = 0.91) measurements.

Conclusion GIUS has a high sensitivity for detecting endoscopic activity. Accordingly, bowel ultrasound has the potential to reduce the number of routine ileocolonoscopies in patients with CD.


Ziel Untersuchung, inwiefern der gastrointestinale Ultraschall (GIUS) in einer heterogenen Krankenhauskohorte mit Morbus Crohn (CD) in der Lage ist, Patienten in endoskopischer Remission von Patienten mit aktiver Erkrankung zu trennen.

Material und Methoden Es wurden prospektiv 145 CD-Patienten, die für eine Ileokoloskopie vorgesehen waren, eingeschlossen. Die endoskopische Krankheitsaktivität wurde mithilfe des „Simple Endoscopic Score for Crohn’s disease“ (SES-CD) quantifiziert, und die Mukosaheilung wurde streng als SES-CD = 0 definiert. Die Remission wurde im Ultraschall als Wandstärke < 3 mm (< 4 mm im Rektum) definiert. Zusätzlich wurde der SES-CD mit Farbdoppler, Harvey-Bradshaw-Index (HBI), C-reaktivem Protein (CRP) und Calprotectin verglichen. Für die Interobserver-Analyse wurden 23 Patienten von 2 Beobachtern untersucht.

Ergebnis Insgesamt 102 Patienten hatten eine aktive Erkrankung und 43 befanden sich in Remission. Der GIUS zeigte eine Sensitivität von 92,2 % und eine Spezifität von 86 % für die Wanddicke und eine Sensitivität von 66,7 % und eine Spezifität von 97,7 % für den Farbdoppler. Für den HBI lag die Sensitivität bei 34,3 % und die Spezifität bei 88,4 %, für CRP betrug die Sensitivität 35,7 % und die Spezifität 82,9 % und für Calprotectin lag die Sensitivität bei 55,9 % und die Spezifität 82,1 %. Die Interobserver-Analyse ergab eine ausgezeichnete Übereinstimmung für die Wanddicke- (k = 0,90) und Farbdoppler-Messungen (k = 0,91).

Schlussfolgerung GIUS hat eine hohe Sensitivität für den Nachweis der endoskopischen Aktivität. Dementsprechend hat der gastrointestinale Ultraschall das Potenzial, routinemäßig durchgeführte Ileokoloskopien bei Patienten mit CD zu reduzieren.

Publication History

Received: 29 November 2019

Accepted: 19 March 2020

Article published online:
24 April 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Peyrin-Biroulet L, Reinisch W, Colombel JF. et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014; 63: 88-95
  • 2 Pariente B, Mary JY, Danese S. et al. Development of the Lemann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology 2015; 148: 52-63; e53
  • 3 Shah SC, Colombel JF, Sands BE. et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther 2016; 43: 317-333
  • 4 Vuitton L, Marteau P, Sandborn WJ. et al. IOIBD technical review on endoscopic indices for Crohn’s disease clinical trials. Gut 2016; 65: 1447-1455
  • 5 Baert F, Moortgat L, Van Assche G. et al Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010; 138: 463-468 ; quiz e410-e461
  • 6 Schoepfer AM, Beglinger C, Straumann A. et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-169
  • 7 Mosli MH, Zou G, Garg SK. et al C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015; 110: 802-819 ; quiz 820
  • 8 Abej E, El-Matary W, Singh H. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2016; 2016: 2483261
  • 9 Maaser C, Sturm A, Vavricka SR. et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019; 13: 144-164
  • 10 Rimola J, Alvarez-Cofino A, Perez-Jeldres T. et al. Comparison of three magnetic resonance enterography indices for grading activity in Crohn’s disease. J Gastroenterol 2017; 52: 585-593
  • 11 Dong J, Wang H, Zhao J. et al. Ultrasound as a diagnostic tool in detecting active Crohn’s disease: a meta-analysis of prospective studies. Eur Radiol 2014; 24: 26-33
  • 12 Maconi G, Nylund K, Ripolles T. et al. EFSUMB Recommendations and Clinical Guidelines for Intestinal Ultrasound (GIUS) in Inflammatory Bowel Diseases. Ultraschall in Med 2018; 39: 304-317
  • 13 Moreno N, Ripolles T, Paredes JM. et al. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn’s disease: changes following treatment with immunomodulators and/or anti-TNF antibodies. J Crohns Colitis 2014; 8: 1079-1087
  • 14 Castiglione F, Testa A, Rea M. et al. Transmural healing evaluated by bowel sonography in patients with Crohn’s disease on maintenance treatment with biologics. Inflamm Bowel Dis 2013; 19: 1928-1934
  • 15 Civitelli F, Nuti F, Oliva S. et al. Looking Beyond Mucosal Healing: Effect of Biologic Therapy on Transmural Healing in Pediatric Crohn’s Disease. Inflamm Bowel Dis 2016; 22: 2418-2424
  • 16 Satsangi J, Silverberg MS, Vermeire S. et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753
  • 17 Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1: 514
  • 18 Daperno M, D’Haens G, Van Assche G. et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-512
  • 19 Sturm A, Maaser C, Calabrese E. et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019; 13: 273-284
  • 20 Nylund K, Maconi G, Hollerweger A. et al. EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound. Ultraschall in Med 2017; 38: e1-e15
  • 21 Spalinger J, Patriquin H, Miron MC. et al. Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology 2000; 217: 787-791
  • 22 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174
  • 23 Ripolles T, Martinez-Perez MJ, Paredes JM. et al. The Role of Intravenous Contrast Agent in the Sonographic Assessment of Crohn’s Disease Activity: Is Contrast Agent Injection Necessary?. J Crohns Colitis 2019; 13: 585-592
  • 24 Allocca M, Fiorino G, Bonifacio C. et al. Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis 2018; 12: 1280-1287
  • 25 Gomollon F, Dignass A, Annese V. et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11: 3-25
  • 26 Novak K, Tanyingoh D, Petersen F. et al. Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn’s Disease: Impact on Clinical Decision Making. J Crohns Colitis 2015; 9: 795-801
  • 27 Serafin Z, Bialecki M, Bialecka A. et al. Contrast-enhanced Ultrasound for Detection of Crohn’s Disease Activity: Systematic Review and Meta-analysis. J Crohns Colitis 2016; 10: 354-362
  • 28 Ripolles T, Martinez MJ, Paredes JM. et al. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology 2009; 253: 241-248
  • 29 Tang MX, Mulvana H, Gauthier T. et al. Quantitative contrast-enhanced ultrasound imaging: a review of sources of variability. Interface Focus 2011; 1: 520-539
  • 30 Zink F, Kratzer W, Schmidt S. et al. Comparison of Two High-End Ultrasound Systems for Contrast-Enhanced Ultrasound Quantification of Mural Microvascularity in Crohn’s Disease. Ultraschall in Med 2016; 37: 74-81
  • 31 Louis E, Mary JY, Vernier-Massouille G. et al Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70; e65 ; quiz e31